21 Jan RheumaGen
Posted at 21:22h
in
Brian Freed, Ph.D., Chief Science Officer
Aurora, Colorado
(Private)
RheumaGen is an engineering cure for rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes (T1D), and other major autoimmune diseases with HLA gene editing. Our approach builds upon clinically proven methods to collect and edit hematopoietic stem cells, which allow us to safely transform harmful HLA alleles into healthy ones. RheumaGen has received excellent initial FDA feedback and is preparing an IND submission to begin Phase I with refractory RA patients in Q1 2026.
